Hogan Thomas E. sold $286K of CLBT

Hogan Thomas E. sold 25,299 shares of Cellebrite DI Ltd. (CLBT) at $11.29 ($0.29M total) on 2026-08-25.

Original reporting
SEC EDGAR · Hogan Thomas E.
Published Aug 27, 2026, 10:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 10:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLBT
Neutral
medium confidence
Mentioned
$CLBT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLBTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock materially, but traders monitoring insider activity may adjust short positions.

02

Market read

Primary insider sale filing; low immediate trading relevance.

03

What to watch

Insider may be diversifying; overall company fundamentals unchanged.

Relevance 4/10Novelty 5/10Timing: post-market filing on 2026-08-27

Background

Cellebrite DI Ltd. provides digital intelligence solutions; insider transactions are regularly disclosed via Form 4.

Company-level read

Ticker impact

$CLBTNeutralMedium confidence
Context

Form 4 filing shows insider sold 25,299 shares for $285,712, reducing holdings to 765,249.

Expected impact

Potential slight downward pressure in short term.

Evidence & confidence

Sale represents ~3.3% of insider's remaining stake; market may view as minor signal.

Market effects

Minimal impact on cybersecurity sector.

No significant regional effect.

Limited to investors tracking insider activity.

Counterpoint

Sale could be routine liquidity need, not a negative signal.

Key entities

  • Cellebrite DI Ltd.

    Cybersecurity and digital forensics firm listed on Nasdaq under CLBT.

  • Hogan Thomas E.

    Officer/director who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CLBTHighAI 8/10

Cellebrite DI Ltd. (CLBT): Financial results for Q3 2026

Cellebrite DI Ltd. (CLBT) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Cellebrite Reports Third-Quarter 2026 Results Third-Quarter ARR Growth of 20% and TTM Free Cash Flow Margin of 31% Net income of $26.7 million; Non-GAAP net income of $45.6 million and adjusted EBITDA of $53.6 million, 36% adjusted EBITDA margin TYSONS CORNER, VA and

$CLBTHigh

Cellebrite Reports Third-Quarter 2026 Results

Cellebrite reported Q3 2026 results with ARR up 20% to $528.5M, revenue up 18% to $149M, and adjusted EBITDA of $53.6M. CEO Shiv Ramji highlighted strong international and U.S. Federal performance, and raised 2026 adjusted EBITDA outlook to $163M-$166M. The company also announced plans to redomicile in the U.S. and progress with its Genesis AI solution.

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.